Tipifarnib, a highly selective and potent farnesyltransferase inhibitor, originally developed by Janssen as a KRAS inhibitor in the early 2000s, has displayed sporadic clinical activity in several unstratified cancer patient populations. Here, KRAS is linked to cancer.